International AIDS Society: Global HIV Vaccine Enterprise: Strategic Plan
The Global HIV Vaccine Enterprise (the Enterprise), hosted by IAS, released its 2018-2023 strategic plan, which aims to address several questions: “How can we maintain the momentum of scientific collaborative efforts while orienting the vaccine community around emerging priorities in late-stage product development? How can we support the vaccine space to respond optimally to results from current efficacy trials? How can we best leverage the IAS’ track record in convening and engaging a diverse range of stakeholders to advance the interests of the HIV vaccine community? How can we heighten political support and expand the Enterprise?” (October 2018).